U.S. Antisense And RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology (RNA Interference, Antisense RNA), By Application (Ocular, Genetic), By Route Of Administration, And Segment Forecasts, 2024 - 2030

Table of Contents

Chapter 1. Methodology and Scope
                     1.1. Market Segmentation & Scope
                     1.2. Segment Definitions
                         1.2.1. Technology
                         1.2.2. Application
                         1.2.3. Route of administration
                         1.2.4. Estimates and forecasts timeline
                     1.3. Research Methodology
                     1.4. Information Procurement
                         1.4.1. Purchased database
                         1.4.2. GVR’s internal database
                         1.4.3. Secondary sources
                         1.4.4. Primary research
                         1.4.5. Details of primary research
                             1.4.5.1. Data for primary interviews in Italy
                     1.5. Information or Data Analysis
                         1.5.1. Data analysis models
                     1.6. Market Formulation & Validation
                     1.7. Model Details
                         1.7.1. Commodity flow analysis (Model 1)
                         1.7.2. Approach 1: Commodity flow approach
                         1.7.3. Volume price analysis (Model 2)
                         1.7.4. Approach 2: Volume price analysis
                     1.8. List of Secondary Sources
                     1.9. List of Primary Sources
                     1.10. Objectives
Chapter 2. Executive Summary
                     2.1. Market Outlook
                     2.2. Segment Outlook
                         2.2.1. Technology
                         2.2.2. Application
                         2.2.3. Route of administration
                     2.3. Competitive Insights
Chapter 3. U.S. Antisense and RNAi Therapeutics Market Variables, Trends, & Scope
                     3.1. Market Lineage Outlook
                         3.1.1. Parent market outlook
                         3.1.2. Related/ancillary market outlook
                     3.2. Market Dynamics
                         3.2.1. Market Driver Analysis
                         3.2.2. Market Restraint Analysis
                     3.3. U.S. Antisense and RNAi Therapeutics Market Analysis Tools
                         3.3.1. Industry Analysis - Porter’s Five Forces
                         3.3.2. PESTEL Analysis
Chapter 4. U.S. Antisense and RNAi Therapeutics Market Technology Estimates & Trend Analysis
                     4.1. U.S. Antisense and RNAi Therapeutics Market Technology Dashboard
                     4.2. U.S. Antisense and RNAi Therapeutics Market Technology Movement Analysis
                     4.3. U.S. Antisense and RNAi Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030
                     4.4. RNA Interference
                         4.4.1. RNA Interference Market estimates and forecasts 2018 to 2030 (USD Million)
                     4.5. Antisense RNA
                         4.5.1. Antisense RNA Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Antisense and RNAi Therapeutics Market: Application Estimates & Trend Analysis
                     5.1. U.S. Antisense and RNAi Therapeutics Market Application Dashboard
                     5.2. U.S. Antisense and RNAi Therapeutics Market Application Movement Analysis
                     5.3. U.S. Antisense and RNAi Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030
                     5.4. Ocular
                         5.4.1. Ocular market estimates and forecasts 2018 to 2030 (USD Million)
                     5.5. Cardio metabolic & Renal Disorders
                         5.5.1. Cardio metabolic & renal disorders market estimates and forecasts 2018 to 2030 (USD Million)
                     5.6. Neurodegenerative Disorders
                         5.6.1. Neurodegenerative Disorders Market estimates and forecasts 2018 to 2030 (USD Million)
                     5.7. Genetic Disorders
                         5.7.1. Genetic Disorders Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Antisense and RNAi Therapeutics Market: Route of Administration Estimates & Trend Analysis
                     6.1. U.S. Antisense and RNAi Therapeutics Market Application Dashboard
                     6.2. U.S. Antisense and RNAi Therapeutics Market Application Movement Analysis
                     6.3. U.S. Antisense and RNAi Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030
                     6.4. Intravenous Injections
                         6.4.1. Intravenous Injections Market Estimates and Forecasts 2018 to 2030 (USD million)
                     6.5. Intrathecal Injections
                         6.5.1. Intrathecal Injections Market estimates and forecasts 2018 to 2030 (USD Million)
                     6.6. Subcutaneous Injections
                         6.6.1. Subcutaneous Injections Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
                     7.1. Recent Developments & Impact Analysis, By Key Market Participants
                     7.2. Company/Competition Categorization
                         7.2.1. Key company market share analysis, 2023
                     7.3. Vendor Landscape
                         7.3.1. Sarepta Therapeutics, Inc
                             7.3.1.1. Company overview
                             7.3.1.2. Financial performance
                             7.3.1.3. Product benchmarking
                             7.3.1.4. Strategic initiatives
                         7.3.2. Ionis Pharmaceuticals, Inc
                             7.3.2.1. Company overview
                             7.3.2.2. Financial performance
                             7.3.2.3. Product benchmarking
                             7.3.2.4. Strategic initiatives
                         7.3.3. Benitec Biopharma, Inc.
                             7.3.3.1. Company overview
                             7.3.3.2. Financial performance
                             7.3.3.3. Product benchmarking
                             7.3.3.4. Strategic initiatives
                         7.3.4. Arbutus Biopharma
                             7.3.4.1. Company overview
                             7.3.4.2. Financial performance
                             7.3.4.3. Product benchmarking
                             7.3.4.4. Strategic initiatives
                         7.3.5. Alnylam Pharmaceuticals, Inc.
                             7.3.5.1. Company overview
                             7.3.5.2. Financial performance
                             7.3.5.3. Product benchmarking
                             7.3.5.4. Strategic initiatives
                         7.3.6. Microsynth AG
                             7.3.6.1. Company overview
                             7.3.6.2. Financial performance
                             7.3.6.3. Product benchmarking
                             7.3.6.4. Strategic initiatives
                         7.3.7. Aragen Bioscience
                             7.3.7.1. Company overview
                             7.3.7.2. Financial performance
                             7.3.7.3. Product benchmarking
                             7.3.7.4. Strategic initiatives
                         7.3.8. Moderna
                             7.3.8.1. Company overview
                             7.3.8.2. Financial performance
                             7.3.8.3. Product benchmarking
                             7.3.8.4. Strategic initiatives
                         7.3.9. Nutcracker Therapeutics
                             7.3.9.1. Company overview
                             7.3.9.2. Financial performance
                             7.3.9.3. Product benchmarking
                             7.3.9.4. Strategic initiatives
                         7.3.10. Deep Genomics
                             7.3.10.1. Company overview
                             7.3.10.2. Financial performance
                             7.3.10.3. Product benchmarking
                             7.3.10.4. Strategic initiatives

List of Tables

Table 1 List of abbreviations
Table 2 U.S. Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Billion)
Table 3 U.S. Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Billion)
Table 4 U.S. Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Billion)

List of Figures

Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 U.S. Antisense and RNAi Therapeutics Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 U.S. Antisense and RNAi Therapeutics Market: Technology outlook and key takeaways
Fig. 15 U.S. Antisense and RNAi Therapeutics Market: Technology Movement Analysis & Market Share 2023 & 2030
Fig. 16 RNA interference market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 17 U.S. Antisense RNA market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 U.S. Antisense and RNAi Therapeutics Market: Application outlook and key takeaways
Fig. 19 U.S. Antisense and RNAi Therapeutics market: Application movement analysis & market share 2023 & 2030
Fig. 20 Ocular market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Cardiometabolic & renal disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Neurodegenerative disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Genetic disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 U.S. Antisense and RNAi Therapeutics Market: Route of Administration outlook and key takeaways
Fig. 25 U.S. Antisense and RNAi Therapeutics market: Route of Administration movement analysis & market share 2023 & 2030
Fig. 26 Intravenous injections market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Intrathecal injections market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Subcutaneous injections market estimates and forecasts, 2018 - 2030 (USD Million)